CNL'S CNRI-H Program Continues Strong Growth Thanks to New Projects With Repare Therapeutics and Defence Therapeutics
3 Articles
3 Articles
CNL announces new projects with leading Canadian biopharmaceutical companies
CHALK RIVER — Canadian Nuclear Laboratories (CNL) is pleased to announce that it is collaborating with two leading Canadian healthcare biotech companies – Repare Therapeutics and Defence Therapeutics – on individual research projects through its Canadian Nuclear Research Initiative – Health (CNRI-H) program. Launched in 2021, the CNRI-H program is designed to accelerate the development of targeted radiopharmaceuticals in Canada through joint res…
CNL'S CNRI-H Program Continues Strong Growth Thanks to New Projects With Repare Therapeutics and Defence Therapeutics
Canada's national nuclear laboratories announces new projects with leading Canadian biopharmaceutical companies through collaborative research program CHALK RIVER, Ontario, Jan. 20, 2025 (GLOBE NEWSWIRE) -- Canadian Nuclear Laboratories (CNL), Canada's premier nuclear science and technology organization, is pleased to announce that it is collaborating with two leading Canadian healthcare biotech companies – Repare Therapeutics and Defence Therap…
Coverage Details
Bias Distribution
- 50% of the sources are Center, 50% of the sources lean Right
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage